2A37 Wagner, John L. - Thomas Jefferson University - Thomas Jefferson University
Dr. Wagner

John L. Wagner, MD

Contact Dr. Wagner

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. A Two-Step Haploidentical Versus a Two-Step Matched Related Allogeneic Myeloablative Peripheral Blood Stem Cell Transplantation
  2. A two-step approach to myeloablative haploidentical transplantation: Low nonrelapse mortality and high survival confirmed in patients with earlier stage disease
  3. Canine immunogenetics
  4. A2-step approach to myeloablative haploidentical stem cell transplantation: A phase 1/2 trial performed with optimized T-cell dosing
  5. Adenovirus DNA polymerase is recognized by human CD8+ T cells
  6. Purification of melanoma reactive T cell by using a monocyte-based solid phase T-cell selection system for adoptive therapy
  7. Port site metastasis of B-cell lymphoma: A first occurrence or an underreported complication?
  8. In vitro methods for generating highly purified EBV associated tumor antigen-specific T cells by using solid phase T cell selection system for immunotherapy
  9. Sequence of the canine major histocompatibility complex region containing non-classical class I genes
  10. Cytoprotection in acute myelogenous leukemia (AML) therapy
  11. Amifostine and autologous hematopoietic stem cell support of escalating-dose melphalan: A phase I study
  12. Activity of single-agent melphalan 220-300 mg/m2 with amifostine cytoprotection and autologous hematopoietic stem cell support in non-Hodgkin and Hodgkin lymphoma
  13. Incidence, risk factors, and mortality from pneumonia developing late after hematopoietic stem cell transplantation
  14. Molecular Organization of the Canine Major Histocompatibility Complex
  15. Cellular, serological, and molecular polymorphism of the class I and class II loci of the canine major histocompatibility complex
  16. Nonmyeloablative conditioning allows for more rapid T-cell repertoire reconstitution following allogeneic matched unrelated bone marrow transplantation compared to myeloablative approaches
  17. Nomenclature for factors of the dog major histocompatibility system (DLA), 2000: Second report of the ISAG DLA Nomenclature Committee
  18. Nomenclature for factors of the dog major histocompatibility system (DLA), 2000: Second report of the ISAG DLA Nomenclature Committee
  19. Pharmacogenetics of methotrexate: Toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism
  20. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects
0